Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic
Women worldwide face risks from pregnancy, HIV, and other sexually transmitted infections (STIs). To date, highly effective contraceptive methods provide no HIV/STI protection, and HIV prevention products, excluding condoms, provide no pregnancy protection. Intravaginal rings (IVRs) delivering antiretrovirals and contraceptives are a promising multipurpose prevention technology (MPT).
Findings provide strong evidence of demand for an MPT IVR that protects from pregnancy and HIV/STIs, lasts longer than 1 month, minimally disrupts menstrual bleeding, and is in women’s control. numberClinicalTrials.gov: #NCT03279120.
September 2022
Click for full info +Full Info:
Resource Type:
Database
Journal Article
Journal Article
MPT Articles
MPT Article
Resource
Citation:
Women worldwide face risks from pregnancy, HIV, and other sexually transmitted infections (STIs). To date, highly effective contraceptive methods provide no HIV/STI protection, and HIV prevention products, excluding condoms, provide no pregnancy protection. Intravaginal rings (IVRs) delivering antiretrovirals and contraceptives are a promising multipurpose prevention technology (MPT).
Findings provide strong evidence of demand for an MPT IVR that protects from pregnancy and HIV/STIs, lasts longer than 1 month, minimally disrupts menstrual bleeding, and is in women’s control. numberClinicalTrials.gov: #NCT03279120.
Authors: Tolley, E.E., Zissette, S., Taylor, J., Hanif, H., Ju, S., Schwarz, J., Thurman, A., Tyner, D., Brache, V. and Doncel, G.F.
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- Contraceptives
- HIVinhibitor
- IVR
- MPTs
Topic(s):
- MPTs
- Development
- Social
Region(s)
- LAC
- United States